Potential of autologous NK cell therapy to eradicate leukemia “Education is [not] the best provision for old age” –Aristotle

OncoImmunology

Volumn 4, Issue 2, 2015, Pages 1-3

  Abdel Azim, Hisham ^b   Heisterkamp, Nora ^a,b,c  

^a Section of Molecular Carcinogenesis   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

ADCC; Adoptive cell therapy; Artificial antigen presenting; Autologous; BP ALL; Expanded NK; Pre B ALL

Indexed keywords

CD19 ANTIBODY; CD3 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 21; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN PRESENTING CELL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL EXPANSION; CELL SPECIFICITY; CELL THERAPY; COCULTURE; CYTOTOXICITY; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; IMMUNOCOMPROMIZED PATIENT; INNATE IMMUNITY; LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; NONHUMAN; TUMOR VOLUME;

EID: 84954507405     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.984549     Document Type: Article

References (10)

1. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 2012; 7:e30264; PMID:22279576; http://dx.doi.org/10.1371/journal.pone.0030264
2. Liu Y, Wu HW, Sheard MA, Sposto R, Somanchi SS, Cooper LJ, Lee DA, Seeger RC. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res 2013; 19:2132-43; PMID:23378384; http://dx.doi.org/10.1158/1078-0432.CCR-12-1243
3. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69:4010-7; PMID:19383914; http://dx.doi.org/10.1158/0008-5472.CAN-08-3712
4. Fei F, Lim M, George AA, Kirzner J, Lee D, Seeger R, Groffen J, Abdel-Azim H, Heisterkamp N. Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. Leukemia 2014; PMID:25134458; http://dx.doi.org/10.1038/leu.2014.246.
5. Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan OC, Dekker CL, Mackey S, Maecker H, Swan GE, et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med 2013; 5:208-145; PMID:24154599; http://dx.doi.org/10.1126/scitranslmed.3006702
6. Bessoles S, Grandclement C, Alari-Pahissa E, Gehrig J, Jeevan-Raj B, Held W. Adaptations of natural killer cells to Self-MHC class I. Front Immunol 2014; 5:349; PMID:25101089; http://dx.doi.org/10.3389/fimmu.2014.00349
7. Brodin P, Karre K, Hoglund P. NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol 2009; 30:143-9; PMID:19282243; http://dx.doi.org/10.1016/j.it.2009.01.006
8. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009; 457:557-61; PMID:19136945; http://dx.doi.org/10.1038/nature07665
9. Parameswaran R, Lim M, Fei F, Abdel-Azim H, Arutyunyan A, Schiffer I, McLaughlin ME, Gram H, Huet H, Groffen J, et al. Effector-Mediated Eradication of Precursor B Acute Lymphoblastic Leukemia with a Novel Fc-Engineered Monoclonal Antibody Targeting the BAFF-R. Mol Cancer Ther 2014; 13:1567-77; PMID:24825858; http://dx.doi.org/10.1158/1535-7163.MCT-13-1023
10. Bachanova V, Miller JS. NK cells in therapy of cancer. Crit Rev Oncog 2014; 19:133-41; PMID:24941379; http://dx.doi.org/10.1615/CritRevOncog.2014011091